Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV000988604 | SCV001138383 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 2 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000994686 | SCV001148373 | uncertain significance | not provided | 2020-03-01 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV001195389 | SCV001365738 | uncertain significance | not specified | 2019-11-06 | criteria provided, single submitter | clinical testing | The p.Arg634Gln variant in MYO7A has been previously reported in an individual with moderate hearing loss who had a truncating MYO7A variant confirmed in trans (He 2018). This variant has been identified in 0.01% (1/8036) in African chromosomes by gnomAD (http://gnomad.broadinstitute.org). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied: PM3, PM2_Supporting, PP3. |
Gene |
RCV000994686 | SCV001988393 | uncertain significance | not provided | 2022-05-04 | criteria provided, single submitter | clinical testing | Observed with multiple variants in the MYO7A gene in a patient with hearing loss in published literature (He et al., 2018); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 29178603) |
Labcorp Genetics |
RCV000994686 | SCV003455423 | uncertain significance | not provided | 2024-07-19 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 634 of the MYO7A protein (p.Arg634Gln). This variant is present in population databases (rs781812509, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with MYO7A-related conditions. ClinVar contains an entry for this variant (Variation ID: 802706). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MYO7A protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001827130 | SCV002086590 | uncertain significance | Usher syndrome type 1B | 2021-05-07 | no assertion criteria provided | clinical testing |